imetelstat

Generic: IMETELSTAT SODIUM·Brand: RYTELO, Rytelo

imetelstat: developed by 1 company · 2 FDA decisions. Updated within the last hour.

Development Pipeline (2)

CompanyPhase
GERON CORP (GERN)Phase 2
GERON CORP (GERN)Approved

FDA Decisions

Approval1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndrom(GERN)
FDA_MeetingODAC meeting on the Company's NDA for imetelstat for transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes after failure of, loss of response to, or ineligibility for ESAs.(GERN)

Frequently asked questions

Who is developing imetelstat?

imetelstat is being developed by GERON CORP.

What is imetelstat's latest FDA decision?

The most recent tracked FDA decision for imetelstat is Approval for 1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndrom, dated June 6, 2024.

Get deeper analysis on imetelstat

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    imetelstat — Drug Pipeline, Trials & FDA Status | BioSniper